Laureate Pharma Becomes Biopharma

Laureate Pharma, Inc. has changed its name to Laureate Biopharmaceutical Services, Inc. to better describe the company’s positioning in the biopharmaceutical industry. The company has also updated its logo to emphasize “Laureate” and to incorporate a laurel wreath, illustrating Laureate Biopharma’s reputation for scientific excellence and commitment to delivery, according to a company statement.

Laureate Biopharma has been in continuous operation in its Princeton, NJ facility since 1981. Since 1996, Laureate Biopharma has focused exclusively on serving other developers in the biotherapeutics market.

“We are building on Laureate Biopharma’s rich history and adding technologies, capacity and staff, while extending our reputation for quality and delivery,” said Michael A. Griffith, Laureate’s chief executive officer. “This name change, although subtle, speaks to our wealth of experience in protein production and a deep scientific bench, which is unique to the industry.”

This name change follows the company’s recent announcement of $20 million in secured capital. Laureate’s previously announced strategically planned improvements are ongoing. These include:

• Adoption of new quality systems technologies
• Upgrade of aseptic fill capabilities
• Upgrade and expansion of protein production facilities and services
• Expansion of mammalian cell line creation services, and
• Launch of a contract analytical testing business